Sio Gene Therapies IncNASDAQ SIOX Stock Report

Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company is headquartered in New York City, New York and currently employs 12 full-time employees. The company went IPO on 2015-06-11. The firm is focused on pushing the boundaries of gene therapy to develop treatments for debilitating rare neurodegenerative diseases, including GM1 gangliosidosis and Tay-Sachs/Sandhoff disease. The firm is primarily focused on pre-clinical research and development initiatives in gene therapy.